Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - hidroklorotiazid; lizinopril - tableta - hidroklorotiazid 12,5 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in diuretiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - fozinopril - tableta - fozinopril 4,8 mg / 1 tableta - fozinopril

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - fozinopril - tableta - fozinopril 4,8 mg / 1 tableta - fosinopril

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - duloksetin - gastrorezistentna kapsula, trda - duloksetin 60 mg / 1 kapsula - duloksetin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - duloksetin - gastrorezistentna kapsula, trda - duloksetin 30 mg / 1 kapsula - duloksetin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - metformin - filmsko obložena tableta - metformin 390 mg / 1 tableta - metformin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - metformin - filmsko obložena tableta - metformin 390 mg / 1 tableta - metformin

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine - okužbe z virusom hiv - antivirusi za sistemsko uporabo - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Evropska unija - slovenščina - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.